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Objective: To establish whether there is an association between TSG-6 activity and osteoarthritis
progression.
Design: TSG-6 activity was determined in 132 synovial ﬂuids from patients with OA of the knee, using a
novel quantitative TSG-6 activity assay. The association between TSG-6 activities at baseline and four
distinct disease progression states, determined at 3-year follow-up, was analyzed using logistic regression.
Results: There was a statistically signiﬁcant relationship between TSG-6 activity at baseline and all OA
progression states over a 3-year period. Patient knees with TSG-6 activities in the top tenth percentile,
compared to the median activity, had an odds ratio (OR) of at least 7.86 (conﬁdence interval (CI) [3.2,
20.5]) for total knee arthroplasty (TKA) within 3 years, and of at least 5.20 (CI [1.8, 13.9]) after adjustment
for confounding factors. Receiver operating characteristic (ROC) analysis for knee arthroplasty yielded a
cut-off point of 13.3 TSG-6 activity units/ml with the following parameters: area under the curve 0.90 (CI
[0.804, 0.996]), sensitivity 0.91 (CI [0.59, 0.99]), speciﬁcity 0.82 (CI [0.74, 0.88]) and a negative predictive
value (NPV) of 0.99 (CI [0.934, 0.994]).
Conclusion: The TSG-6 activity is a promising independent biomarker for OA progression. Given the high
NPV, this assay may be particularly suitable for identifying patients at low risk of rapid disease pro-
gression and to assist in the timing of arthroplasty.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Biomarkers are objective indicators of normal biologic processes,
pathogenic processes, or responses to therapeutic intervention1.
Radiologic staging, patient symptoms, and osteoarthritis (OA) risk
factors such as age, gender and body mass index (BMI) have limited
value for predicting the risk of rapid OA progression2e4. As a result,
progression of OA is highly unpredictable. Therefore there is a need
to identify biomarkers of OA progression. Although candidate bio-
markers have been investigated, their practical use is still very
limited and new and better biomarkers are needed5,6. In OA of the
knee, biomarkers of disease progression could be of particular valueH.-G. Wisniewski, New York
iology, 550 First Avenue, New
2-263-8276.
edu (H.-G. Wisniewski).
s Research Society International. Pto assist in decisions regarding the timing of total knee arthroplasty
(TKA) or the implementation of long-term lifestyle changes such as
weight loss or activity modiﬁcation. Biomarkers of OA progression
are also of particular interest for aiding development of disease-
modifying OA drugs (DMOADs)5. Although not currently available,
several potential DMOADs have shown efﬁcacy in OA models and
are in development for treatment of OA in humans7. Potential side
effects of such drugs or other constraints may restrict their use to
patients with the most serious disease or those at highest risk of
rapid progression. Thus, biomarkers of OA progression would be
useful for identifying high-risk patients who would beneﬁt most
from the use of DMOADs. They could also be used for identifying
high-risk patients for inclusion in clinical trials, thereby improving
study power over current methods5,8.
TNFAIP-6, encoded by TNF-stimulated gene 6 (TSG-6), and
commonly known as TSG-6 protein9, is a hyaluronan (HA) binding
protein associated with inﬂammation10,11. Potent anti-inﬂammatoryublished by Elsevier Ltd. All rights reserved.
Table I
Synovial ﬂuid TSG-6 activity by knee OA progression status (N ¼ 132)
Outcome category N % Mean (median)
TSG-6 activity (u/ml)
SD
NP 60 45.5 6.94 (6.12) 4.35
OSTþ/JSN 49 37.1 9.87 (8.5) 5.72
OSTþ/JSNþ 12 9.1 12.68 (11.16) 6.05
TKAþ 11 8.3 22.61 (21.4) 11.47
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strated in experimental arthritis models12e16. TSG-6 inhibits both
osteoblast differentiation and osteoclast activation17,18. TSG-6 me-
diates the transfer of heavy chains (HCs) from inter-a-inhibitor (IaI)
to HA, resulting in the formation of covalent HAeHC complexes19e21,
and has an essential role in the stabilization of the HA-rich extra-
cellular matrix of cumulus celleoocyte complexes during ovulation,
resulting in infertility of female TSG-6-deﬁcient mice22.
Expression of TSG-6 is induced by pro-inﬂammatory cytokines,
growth factors and hormones23e27, resulting in a complex expres-
sion pattern. Presence of TSG-6 has been demonstrated in synovial
ﬂuids of patients with either OA or rheumatoid arthritis (RA) and
also in cartilage of both OA and RA patients28e30. However, no
quantitative studies of TSG-6 in OA or RA patient specimens have
been performed and the potential of TSG-6 as a biomarker in these
diseases has not yet been explored.
Because a TSG-6 ELISA sufﬁciently sensitive and speciﬁc to be
used with biological ﬂuids is currently not available, we developed
an assay that measures the TSG-6 activity in synovial ﬂuid under
conditions very close to in vivo conditions. In this study, we
analyzed the association of TSG-6 activity, determined retrospec-
tively in synovial ﬂuids collected at baseline, with data from a
prospective natural history study of OA progression. Our hypothesis
was that the TSG-6 activity at baseline might predict progression of
OA over a period of 3 years.
Method
Reagents
Covalink-NH plates were purchased from Nunc (Thermo Fisher
Scientiﬁc, Pittsburgh, PA). HA was purchased from Lifecore
Biomedical (Chaska, MN). Rabbit anti-human IaI and biotinylated
goat anti-rabbit Ig were from Dako (Carpinteria, CA), and
streptavidin-alkaline phosphatase conjugate was purchased from
Invitrogen (Grand Island, NY). Sulfo-NHS was from Pierce (Thermo
Fisher Scientiﬁc, Rockford, IL), and EDC and p-nitrophenyl phos-
phate were purchased from Sigma (St. Louis, MO).
OA patient population and sample preparation
We analyzed 132 synovial ﬂuid samples from 91 patients
enrolled in the NIH-sponsored POP (Strategies to Predict OA Pro-
gression) study. This study was conducted at Duke University. All
procedures were in accordance with the ethical standards of the
Helsinki Declaration of 1975, as revised in 2000, andwere approved
by the Duke University Institutional Review Board with informed
consent being obtained from all subjects. The approval authorizes
the use of the specimens for the current study. All human speci-
mens analyzed in the current study were provided in a de-
identiﬁed form. All synovial ﬂuids included in this study were
collected without lavage and cell free supernatants were prepared
and frozen (80C) within 1 h of collection. Blood samples ob-
tained from some OA patients enrolled in this study were centri-
fuged at 3500 rpm for 10min and serum stored in 1 ml aliquots and
frozen (80C) until analyzed. Matched synovial ﬂuids (N ¼ 30)
and sera were available for 21 individuals (including synovial ﬂuid
from both knees of nine patients). Inclusion and exclusion criteria
for this study and details of the radiographic assessment of OA
progression have been described31. All participants met radio-
graphic criteria for knee OA based on KellgreneLawrence (KL)
grades 1e332 and American College of Rheumatology criteria for
symptomatic OA of at least one knee33. In addition, contralateral
knees with symptomatic and/or radiographic OA were also sur-
veyed resulting in the availability of knees of all OA severity grades(KL grades 0e4) for this study. 88 of the 91 patients in this study
group had bilateral radiographic OA based on a baseline KL grade of
1. Demographic information on the study population can be
found in Supplemental Table I and information regarding baseline
KL grades can be found in Supplemental Table II. Progression of the
disease over a 3-year period was determined by comparison of
standardized radiographs taken at baseline and at a 3-year follow-
up evaluation31. In addition to KL grades, individual joints were
scored for osteophytes (OST, range 0e12 per knee) and joint space
narrowing (JSN, range 0e6 per knee) using the standardized OARSI
atlas34 of individual radiographic features in OA. Details of the
scoring and the inter-rater reliability of scoring have been
described35. An increase in the OST scores between baseline and
follow-up was designated progression based on OST formation
(OSTþ), while an increase in the JSN score was designated pro-
gression based on JSN (JSNþ). All joints that showed progressive
JSN also showed progression of OST formation. Mutually exclusive
outcome groups were used consisting of non-progressors (NP), OST
progressors (OSTþ/JSN), JSN progressors (OSTþ/JSNþ), and TKA
progressors (TKAþ), i.e., patients who underwent TKA for end-
stage OA sometime during the 3-year interval from baseline to
follow-up. Radiological progression data for all patient knees are
shown in Table I. A small number (N ¼ 5) of synovial ﬂuids from
humans without known symptoms of joint disease were procured
from the National Disease Research Interchange (NDRI). These
specimens were collected at autopsy and stored frozen at 80C.
Their use in de-identiﬁed form in the current study was in accor-
dance with the ethical standards of the Helsinki Declaration of
1975, as revised in 2000, and was approved by the institutional
review board of New York University.
Recombinant TSG-6 protein
Recombinant TSG-6 protein was expressed in BTI-TN-5B1-4 in-
sect cells and puriﬁed as described19.
TSG-6 activity assay
The TSG-6 activity assay was carried out in a blinded fashion
with respect to the clinical progression status of the samples. HA
was coupled covalently to Covalink-NH plates (96-well plates) as
described19. The plates were blocked by overnight incubation at
37C with 0.5% casein in Tris-buffered saline (TBS: 20 mM Tris,
500 mM NaCl, pH 8.0) and stored at 4C for up to several months.
The TSG-6 activity assay was based on an assay for recombinant
TSG-6 using exogenous IaI19. In contrast to the earlier assay, the
assay used here exclusively relies on IaI present in the analyzed
synovial ﬂuid or serum sample. Synovial ﬂuid or serum samples
were diluted 1:100 in PBS and incubated for 2 h at 37C (100 ml per
well, 2 wells per sample) in Covalink-NH plates to which HA had
been coupled (see above). After washing 3 with 200 ml of TTBS
(20 mM Tris, 500 mM NaCl, 0.1% Tween-20, pH 7.5, used for
washing between all incubation steps), wells were incubated for 1 h
at 37C with a polyclonal rabbit anti-IaI speciﬁc for HCs diluted
1:1000 in TTBS, followed by incubations with biotinylated goat
Table II
Statistical test results for comparisons of median TSG-6 activities between different
outcome groups
Outcome Differences between median TSG-6 activities (in u/ml)
of outcome groups and (P-values for differences*)
TKAþ OSTþ/JSNþ OSTþ/JSN
NP 15.28 (<0.0001) 5.04 (0.002) 2.38 (0.004)
OSTþ/JSN 12.9 (0.0001) 2.66 (0.09)
OSTþ/JSNþ 10.24 (0.02)
In addition, the difference between themedian TSG-6 activity of TKA joints and non-
TKA joints was 13.8 m/ml and statistically signiﬁcant (P ¼ 0.002), while the differ-
ence between the median TSG-6 activity of NP joints and progressor joints
(including OSTþ/JSN, OSTþ/JSNþ, and TKA joints) was 3.78 u/ml and also statis-
tically signiﬁcant (P < 0.0001).
* Using the nonparametric WilcoxoneManneWhitney test.
H.-G. Wisniewski et al. / Osteoarthritis and Cartilage 22 (2014) 235e241 237anti-rabbit IgG (1:1000 in TTBS, 1 h at 37C), streptavidin-alkaline
phosphatase conjugate (1:1000 in TTBS, 1 h at 37C), and ﬁnally
with p-nitrophenyl phosphate (2 mg/ml in 50 mM Tris, 2 mM
MgCl2, pH 9.5). After about 5e30 min at 37C the absorbance at
410 nm was measured, using 750 nm as a reference wavelength.
The TSG-6 activity was expressed in units/ml (u/ml). 1 u/ml of TSG-
6 activity in a biological sample (synovial ﬂuid or serum) was
deﬁned as the HC transfer activity equivalent to the activity of a
standard of 1 nM recombinant TSG-6 under standardized condi-
tions, i.e., in a volume of 100 ml PBS containing a human plasma
standard at 1:1000 (as source of IaI) and incubated at 37C for 2 h.
This TSG-6 standard was included in each assay (six wells per
plate). A single batch of human plasma and recombinant TSG-6 was
used throughout this study, and both standard reagents were
stored frozen in aliquots at 80C. PBS was included as a negative
control. The TSG-6 activity was calculated as the ratio between the
mean absorbance of a sample and the TSG-6 standard, multiplied
by the dilution factor of the sample (i.e., 100).Statistics
Logistic regression was used to estimate the association be-
tween TSG-6 activity and OA progression based on the above-
deﬁned outcome categories while controlling for covariates (for
details, see Table III). The associationswere expressed as odds ratios
(ORs) of progression associated with a one-unit increase of TSG-6
activity. The regression was adapted to correlated data, due to the
presence of contralateral knees, using generalized estimating
equations (GEE)36,37. Median TSG-6 activities of synovial ﬂuid
samples from non-arthritic and OA knees, and median TSG-6Table III
Logistic regression analysis of the association of the TSG-6 activity in synovial ﬂuid at bas
using GEE
Response OR (P-value) (CI)
TKAþ (N ¼ 11) No progression (/)
(N ¼ 60)
O
(N
No adjustment 1.23 (<0.00001)
(1.12, 1.35)
0.858 (0.000363)
(0.788, 0.934)
1.
(1
Adjusted for BMI, age,
gender
1.23 (<0.00001)
(1.13, 1.35)
0.864 (0.000687)
(0.794, 0.940)
1.
(1
Adjusted for BMI, age,
gender, pain
1.19 (<0.0001)
(1.1, 1.3)
0.865 (0.000726)
(0.795, 0.941)
1.
(1
Adjusted for BMI, age,
gender, pain, X-ray grade
1.18 (0.00161)
(1.06, 1.3)
0.896 (0.0126)
(0.822, 0.978)
1.
(0
CI, 95% conﬁdence interval.
The OR shown is for a 1 u/ml incremental increase of the TSG-6 activity.
All adjustments for covariates refer to baseline data.activities of synovial ﬂuid samples from different OA outcome
groups (Table II) were compared using the nonparametric Wil-
coxoneManneWhitney test. Receiver operating characteristic
(ROC) analysis was employed to evaluate the performance of the
TSG-6 activity assay38. Youden’s index was used to estimate the
optimal decision threshold for the differentiation of TKA and non-
TKA patient knees39. All computations were performed using R
software, version 2.15.0.Results
Quantitative assessment of the TSG-6 activity in synovial ﬂuids of
OA patients
We determined the TSG-6 activity in synovial ﬂuid samples
from 132 OA patient knees. Fig. 1 shows a box plot of the distri-
bution of the TSG-6 activities in the four outcome groups, i.e., NP,
OSTþ/JSN, OSTþ/JSNþ, and TKA within the 3-year follow-up
period. Descriptive statistics including sample sizes, percentage of
the different outcome groups, mean and median TSG-6 activities,
and standard deviations are listed in Table I. Pairwise comparison of
the four outcome groups, using the nonparametric Wilcoxone
ManneWhitney test, showed that the median TSG-6 activity of the
NP group and the TKA group were statistically signiﬁcantly
different from each other and from all other outcome groups
(Table II). The median TSG-6 activity of the group with exclusive
OST progression and the group with both OST progression and JSN
did not signiﬁcantly differ from each other. In addition, a compar-
ison between selected combinations of outcome groups is very
instructive. Most notably, the difference between themedian TSG-6
activity of TKA joints and non-TKA joints (including NP, OSTþ/JSN
and OSTþ/JSNþ joints) was 13.92 u/ml and statistically signiﬁcant
(P ¼ 0.002). In addition, the difference between the median TSG-6
activity of NP joints and progressor joints (including OSTþ/JSN,
OSTþ/JSNþ, and TKA joints) was 5.35 u/ml and it was also statis-
tically signiﬁcant (P < 0.0001). Of note, in patients for which
matched synovial ﬂuid (N ¼ 30) and serum samples (N ¼ 21) were
available, TSG-6 activity was higher in synovial ﬂuid than serum in
76.7 % of samples (16.56  13.44 u/ml in synovial ﬂuid of vs
5.62  4.68 u/ml in serum) supporting a joint tissue origin of this
marker. Interestingly, the few patients (7 of 30) that had higher
TSG-6 activity in serum than in synovial ﬂuids were all NP. Overall
there was a non-signiﬁcant correlation between TSG-6 activity in
synovial ﬂuid and serum (r ¼ 0.11, P ¼ 0.58). A comparison of the
TSG-6 activity in synovial ﬂuids of OA patients (9.85  7.21 u/ml,
median ¼ 7.98 u/ml, N ¼ 132) with that in specimens from humans
without known joint disease (3.031.70 u/ml, median¼ 2.99 u/ml,eline with OA progression over 3 years represented by different outcome categories,
STþ/JSNþ
¼ 12)
TKAþ or OSTþ/JSNþ
(N ¼ 23)
Any progression (TKAþ, OSTþ/JSN,
OSTþ/JSNþ) (N ¼ 72)
13 (0.0231)
.02, 1.26)
1.20 (<0.0001)
(1.1, 1.31)
1.18 (<0.0001)
(1.09, 1.28)
14 (0.0179)
.02, 1.27)
1.20 (<0.0001)
(1.11, 1.31)
1.18 (<0.0001)
(1.09, 1.27)
14 (0.0171)
.02, 1.27)
1.19 (0.00012)
(1.09, 1.3)
1.18 (<0.0001)
(1.09, 1.27)
12 (0.0526)
.997, 1.26)
1.16 (0.00162)
(1.06, 1.27)
1.13 (0.00125)
(1.05, 1.22)
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Fig. 1. TSG-6 activities in synovial ﬂuid by knee OA progression status. Shown is a box
plot of TSG-6 activities in four OA outcome categories: NP (N ¼ 60), OST only pro-
gressors (OSTþ/JSN, N ¼ 49), JSN progressors (OSTþ/JSNþ, N ¼ 12), and TKA pro-
gressors (N ¼ 11), as indicated. The boxes indicate 10%, 25%, 75% and 90% quantiles and
the median for each outcome group. The line indicates the mean of the whole sample
(N ¼ 132, mean ¼ 9.85 u/ml).
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Fig. 2. ROC curve for the TSG-6 activity assay and the outcome TKA vs non-TKA. The
area under the curve is 0.90. A TSG-6 cut-off point of 13.3 u/ml, determined by You-
den’s index, yielded a sensitivity of 0.91 and a speciﬁcity of 0.82.
Table IV
Contingency table for the TSG-6 activity assay for the condition TKA vs non-TKA and
a cut-off point of 13.3 u/ml
TKA positive TKA negative
Test positive TP ¼ 10 FP ¼ 22 PPV ¼ 0.31
Test negative FN ¼ 1 TN ¼ 99 NPV ¼ 0.99
Sensitivity 0.91 Speciﬁcity 0.82
TP, true positives; FP, false positives; TN, true negatives; FN, false negatives. The
positive likelihood ratio (LRþ) is 5.06, and the negative likelihood ratio (LR) is 0.11.
H.-G. Wisniewski et al. / Osteoarthritis and Cartilage 22 (2014) 235e241238N ¼ 5) suggested elevated TSG-6 activities in OA patients. The
difference between themedian TSG-6 activities of these two groups
was statistically signiﬁcant (P ¼ 0.004).
Logistic regression analysis of TSG-6 activity and clinical progression
status
The results of logistic regression analysis, shown in Table III,
estimate the ORs for speciﬁc outcomes of OA progression associ-
ated with a 1 u/ml increase of the TSG-6 activity in synovial ﬂuid
fromOA patients collected at baseline. The ORs are greater than one
for all categories of progression but less than one for non-
progression. The OR is highest for TKA as outcome, and generally
higher for more severe radiographic outcome categories than for
less severe ones.
The OR for progression to TKA associated with an increase in
TSG-6 activity of 1 u/ml is 1.23, with a range of TSG-6 activities
between 0 and 49.6 u/ml for the full dataset. The OR for progres-
sion to TKA for patients in the top tenth percentile of TSG-6 ac-
tivities is particularly informative. Patient knees in the top tenth
percentile of TSG-6 activities had TSG-6 values of 17.94 u/ml or
more (up to 49.6 u/ml), i.e., at least 9.96 u/ml above the median
TSG-6 activity of 7.98 u/ml for the whole sample. Compared to the
median TSG-6 activity, this translates into an OR for progression to
TKA of at least 7.86 (¼ 1.239.96, conﬁdence interval (CI) [3.2, 20.5]).
After adjusting for covariates, including BMI, age, gender, pain
severity, and radiographic grade (all baseline values), the OR for
progression to TKA for patient-knees in the top tenth percentile as
compared to the median TSG-6 activity is at least 5.20 (¼ 1.189.96,
CI [1.8, 13.9]).
ROC analysis of the TSG-6 activity data for the determination of
progression to TKA vs all other outcome groups is shown in Fig. 2.
The area under the curve is 0.90 (CI [0.804, 0.996]). Application of
the Youden index suggested 13.3 u/ml as an approximation for the
optimal cut-off point39. For this threshold, the sensitivity of the
assay is 0.91 (CI [0.59, 0.99]), its speciﬁcity is 0.82 (CI [0.74, 0.88]),
the positive predictive value (PPV) is 0.31 (CI [0.22, 0.95]), and the
negative predictive value (NPV) is 0.99 (CI [0.934, 0.994]). A con-
tingency table with additional parameters and information about
true and false positives, and true and false negatives is shown in
Table IV.Discussion
The presence of TSG-6 in synovial ﬂuid and cartilage of patients
with a spectrum of joint diseases, including OA and RA, has been
demonstrated using immunological techniques28e30. Using a
different approach, Marshall et al.40 reported decreased expression
of TSG-6 in blood leukocytes from patients with mild OA compared
to non-arthritic subjects. In contrast, Appleton et al.41 determined
that expression of the TSG-6 gene was upregulated in chondrocytes
of rats during early experimental OA. Furthermore, a single nucle-
otide polymorphism (SNP) in the TSG-6 gene has been linked to the
risk of knee OA42. A possible linkage between TSG-6 and OA was
also found in another genome-wide linkage analysis43. None of
these studies analyzed the association of TSG-6 gene expression,
TSG-6 protein concentration, or TSG-6 activity with disease
progression.
We developed an activity assay for the purpose of quantifying
TSG-6 in biologic ﬂuids. An ELISA for TSG-6 suitable for determining
TSG-6 in serum or synovial ﬂuids has not yet been developed, and
our own efforts have not been successful. The protocol for the ac-
tivity assay is very similar to that of a sandwich ELISA; the main
differences are that immobilized HA replaces the capture antibody
and that HA-bound HC, rather than antibody-bound TSG-6, is then
quantiﬁed using an anti-HC detection antibody.
Our study has two main ﬁndings: (1) there is a general associ-
ation between the TSG-6 activity at baseline and subsequent OA
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study, and (2) the one outcome groupmost clearly set apart by high
TSG-6 activity is the one comprising patients who underwent TKA
within 3 years, a group that can be considered to have progressed to
end-stage OA.
The strong association of a very high TSG-6 activity with rapid
progression to end-stage OAwas supported by an OR of at least 7.86
for TKA within 3 years for patient knees within the top tenth
percentile of TSG-6 activities, compared to the median TSG-6 ac-
tivity. 54.5% of patient knees in the top tenth percentile of TSG-6
activity progressed to TKA. An OR of greater than 5.20 for this
same group, after adjustment for covariates (Table III), identiﬁed
TSG-6 activity as a promising independent biomarker for OA pro-
gression over 3 years.
Parameters derived from the ROC curve analysis, such as the
area under the curve (0.90), sensitivity (0.91) and speciﬁcity (0.82)
suggest that the TSG-6 activity assay performs very well in
discriminating between OA patients at high or low risk of rapid
progression to end-stage OA. In contrast to sensitivity and speci-
ﬁcity, the predictive values of the assay are also affected by the low
prevalence of TKA in our sample (8.3 % over 36 months). Of note,
this rate of TKA in our sample was roughly similar to the risk of TKA
of 8.8 % over a 30-month period for OA patients with consistent
frequent knee pain in the much larger MOST study44.
The low prevalence of TKA patients works in favor of the NPV
and against the PPV. This is most clearly demonstrated by the very
high NPV of 0.99 for our test sample, i.e., 99% of all negative test
results were true negatives. Therefore, it should be emphasized
that the assay may be particularly suitable for identifying patients
who are at low risk of rapid progression to end-stage disease. In our
patient sample, 46.7% (28 of 60) of NP knees had KL scores of three
or four at baseline, indicating advanced radiologic OA. 85.7% (24 of
28) of these cases were identiﬁed to be at low risk for TKA by virtue
of a TSG-6 activity below the threshold of 13.3 u/ml. A low TSG-6
activity might encourage patients and surgeons to consider non-
surgical treatment options and lifestyle modiﬁcations that require
more time.
Although the speciﬁcity of the assay is 0.82, the observed PPV of
0.31 indicates a higher rate of false positive test results, i.e., knees
with TSG-6 activities above the threshold that did not have TKA.
This is, partially, a consequence of the low prevalence of TKA pa-
tients and makes the identiﬁcation of high-risk patients inherently
more difﬁcult. This will require a more differentiated approach to
identifying true high-risk patients among the test positives, but
also efforts to control certain causes of false positive test results in
future studies. While TKA is an attractive endpoint in clinical
studies45, it has peculiarities that may have increased the rate of
false positives in our study. Factors unrelated to OA, such as
comorbidities, age, patient willingness or procedure affordability,
may prevent or delay TKA and are potential causes for false positive
test results. The correct classiﬁcation of such cases in future studies
could potentially improve the accuracy of identifying high-risk
patients using the TSG-6 activity assay. Importantly, the evalua-
tion of the individual risk of OA progression is not limited to a high
vs low risk prediction. Individual odds of progression can be esti-
mated on a continuous scale, thereby providing much more
detailed information for individual patients. A very high TSG-6
activity may support a decision to undergo TKA. When DMOADs
become available, adverse side effects and cost may increase the
need to identify high-risk patients for whom DMOAD therapy has a
favorable riskebeneﬁt ratio. The ability to differentiate low-risk
and high-risk patients could also be very valuable for clinical tri-
als of DMOADs. By excluding prospective low-risk patients, who are
unlikely to progress and therefore to beneﬁt from DMOAD treat-
ment, the power of the trial could be increased. In addition, becauseTSG-6 activity reﬂects a composite response to multiple pro-
inﬂammatory mediators23,24, among other factors25e27, OA pa-
tients with high TSG-6 activity may constitute a subset for whom
anti-inﬂammatory treatment strategies may be particularly
beneﬁcial.
A limiting factor for the clinical application of the TSG-6 activity
is the availability of OA synovial ﬂuid specimens. However, among
patients with mid-or late-stage OA, the increasing likelihood of
effusions or of intra-articular drug injections provides opportu-
nities to collect synovial ﬂuid. This group represents the patient
population with a particular need to estimate the individual risk of
OA progression.
Another limitation of this study is the small number of patients
with TKA or progressive JSN, a result of their low prevalence.
However, despite the low number of TKA patients, the P-value of
the OR for progression to TKA is very low (<0.00001, Table III).
Exploratory statistical analysis, logistic regression and ROC
analysis strongly suggest that the TSG-6 activity is a promising
independent biomarker of OA progression, in particular to end-
stage disease. Further prospective studies in different patient
populations are needed to verify these ﬁndings.Contributions
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